Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In clinical trials, baricitinib showed significant hair regrowth in patients with severe alopecia areata, especially those with a SALT score of 50 or higher, according to this research. Baricitinib is noted as an alternative to corticosteroids and other JAK inhibitors.

Baricitinib effectively regrew hair in a woman with alopecia universalis after other treatments failed.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

This study found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg for treating severe alopecia areata at Weeks 24 and 52, potentially influencing reimbursement decisions.

This study evaluated a natural, herbal-based powder formulation aimed at removing unwanted facial hair while promoting skin health, finding that the product was effective and well-suited for use based on physical properties and user feedback.

This study found that escalating baricitinib to 6 mg daily improved hair loss in 75% of patients with severe refractory alopecia areata who responded poorly to standard treatments, while also noting manageable short-term safety concerns under close monitoring.

In this case report, a 60-year-old woman with alopecia areata and type 1 diabetes experienced hypoglycemic seizures after starting baricitinib, though reducing the dose alleviated these episodes; the study highlights the need for caution and glucose monitoring when using JAK inhibitors in at-risk patients.

In this case study, the authors reported a post-bariatric surgery patient who developed acne due to inappropriate vitamin supplementation, emphasizing the need for careful monitoring and education on vitamin use to prevent complications in such patients.

This study evaluated baricitinib 4 mg treatment in severe to very severe alopecia areata, reporting significant scalp hair regrowth by Week 52, especially in short-duration episodes, suggesting treatment should continue for at least a year before assessing failure.

This study documented a case where the medication baricitinib effectively promoted hair regrowth in a woman with alopecia areata but also led to an unexpected side effect of hypertrichosis, suggesting a need to further explore the JAK/STAT pathway's role in hair growth dynamics.

This study investigated the effects of mesotherapy on alopecia in patients who had bariatric surgery, highlighting significant roles of individual, behavioral, and structural factors, though specific results were not fully detailed in the abstract.

In this study, patients with severe alopecia areata who were treated with baricitinib 4 mg/day for 48 weeks showed significant improvements in both hair regrowth and nail abnormalities, although the correlation between hair and nail improvement was weak.

In this retrospective case series, baricitinib showed effectiveness in treating alopecia areata, with some potential benefits for psoriasis, but it may not be suitable for managing psoriatic arthritis in patients with these coexisting conditions.

Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.

This study concluded that hair loss is a common issue after vertical sleeve gastrectomy, influenced by serum leucine concentration, and is not typically due to low iron or zinc levels.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

This study observed that baricitinib led to significant hair regrowth and improved psychological well-being in severe alopecia areata patients over 48 weeks, with 63.2% achieving a SALT score of ≤20.

This study found that elevated tissue RBP4 levels correlate with disease severity in alopecia areata and decrease after effective baricitinib treatment, while the rs3758539 polymorphism is linked to disease susceptibility but not to treatment response.

In this study, Saudi Arabian adults experienced high rates of long-term complications and significant weight regain more than 5 years after bariatric surgery, emphasizing the need for ongoing follow-up and nutritional management to address these issues.

This study found that six months after bariatric surgery, Latvian patients experienced significant improvements in quality of life, weight loss, and resolution of some obesity-related symptoms, although hair loss was a common postoperative effect.

This case report presents the first instance of a pediatric alopecia areata patient switching from baricitinib to ritlecitinib, demonstrating favorable clinical outcomes, suggesting a potential new treatment pathway for children with severe cases of this condition.

This study suggests that integrating barber care with medical treatment improves scalp condition and psychological well-being in early stages of hair loss, by enhancing medication efficacy and reducing stress.

This study found that baricitinib is effective for treating severe alopecia areata, with significant hair regrowth observed by the third month of therapy and continued improvement by month 12, while adverse events were mainly mild.

This study reports that baricitinib was effective and well-tolerated over 52 weeks for severe alopecia areata, with significant improvements in disease severity and no serious adverse events.

In this study, baricitinib showed effectiveness and good tolerability in treating severe alopecia areata over 52 weeks.

Results are not reported in this abstract, which notes that while Janus kinase inhibitors like baricitinib show therapeutic benefits for alopecia areata, the mechanisms and reliable predictors of response remain unclear.

The researchers reported that baricitinib treatment for at least 52 weeks reduced severe alopecia areata severity and improved psychological well-being and quality of life in study participants.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.

In this study, baricitinib, a JAK inhibitor, was found to significantly improve scalp hair regrowth in both adults and adolescents with severe alopecia areata, with many achieving nearly full regrowth by weeks 36 or 52.

This study found that approximately 85% of adults with severe alopecia areata who responded to baricitinib at 52 weeks maintained their improvement over a span of four years.